XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Locally Advanced Differentiated Thyroid Gland Carcinoma · Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma · Locally Advanced Thyroid Gland Follicular Carcinoma · Locally Advanced Thyroid Gland Oncocytic Carcinoma · Locally Advanced Thyroid Gland Papillary Carcinoma · Metastatic Differentiated Thyroid Gland Carcinoma · Metastatic Poorly Differentiated Thyroid Gland Carcinoma · Metastatic Thyroid Gland Follicular Carcinoma · Metastatic Thyroid Gland Oncocytic Carcinoma · Metastatic Thyroid Gland Papillary Carcinoma · Refractory Differentiated Thyroid Gland Carcinoma · Refractory Poorly Differentiated Thyroid Gland Carcinoma · Refractory Thyroid Gland Follicular Carcinoma · Refractory Thyroid Gland Oncocytic Carcinoma · Refractory Thyroid Gland Papillary Carcinoma · Stage III Differentiated Thyroid Gland Carcinoma AJCC v8 · Stage III Thyroid Gland Follicular Carcinoma AJCC v8 · Stage III Thyroid Gland Papillary Carcinoma AJCC v8 · Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 · Stage IV Thyroid Gland Follicular Carcinoma AJCC v8 · Stage IV Thyroid Gland Papillary Carcinoma AJCC v8

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Harbor-UCLA Medical Center, Torrance, California, United States
Contact: Study coordinator (Andrew Gianoukakis, MD) · ResearchGo@mednet.ucla.edu · (424) 306-4000
Contact: Principal Investigator (Andrew Gianoukakis, MD)
Northwestern University, Chicago, Illinois, United States
Contact: Study coordinator (Jochen H. Lorch, MD) · jochen.lorch@nm.org · 312-694-6959
Contact: Principal Investigator (Jochen H. Lorch)

Study leads

Jochen H Lorch
Principal Investigator
Northwestern University

View source on ClinicalTrials.gov